HIV Infections
Conditions
Brief summary
This is an open-label, randomized and multi-center study to compare the efficacy and safety of continued enfuvirtide (Fuzeon) plus (+) OB therapy versus OB alone in participants with HIV-1 infection. Participants will receive an initial 28 week induction treatment with enfuvirtide + OB. After 28 weeks participants with a plasma viral load less than or equal to (\</=) 400 copies/milliliter (mL) at Week 16 and less than (\<) 50 copies/mL at Week 24 will be randomized in the ratio 1:1 to receive either enfuvirtide + OB or OB alone for another 24 weeks (up to Week 52).
Interventions
DRUGEnfuvirtide
Participants will receive 90 mg enfuvirtide subcutaneously (SC) b.i.d.
DRUGOptimized background antiretroviral regimen (OB)
Participants will receive OB (nucleoside and or non-nucleoside reverse transcriptase inhibitor and protease inhibitor) as per investigator's discretion. Protocol does not specify any particular OB drugs.
Sponsors
Hoffmann-La Roche
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants with HIV-1 infection * Female participants without any risk of pregnancy * Participants previously treated with drugs of 2 or 3 different antiretroviral classes * Participants currently on highly active antiretroviral treatment (HAART) for more than 4 weeks and with a plasma viral load between 1,000 and 300,000 copies of HIV-1 ribonucleic acid per milliliter (RNA/mL) * Participants with the possibility of potentially effective OB without enfuvirtide, consisting to 2 to 5 drugs, at least two of which are active from at least two different antiretroviral classes * Cluster of differentiation 4 (CD4) cell count greater than (\>) 50 cells/cubic millimeter (mm\^3) at screening * Participants in whom resistance mutations have been detected in reverse transcriptase and/or protease genes * Enfuvirtide-naive participants
Exclusion criteria
* Women of childbearing age not using effective mechanical contraception * Pregnant or breastfeeding women * Presence of HIV-2 coinfection * Participants participating or having participated to another clinical trial during the 30 days prior to selection for this trial * Participants having previously been treated with enfuvirtide * Presence active opportunistic infection within 1 month of study entry * Existence of Grade 4 clinical or laboratory abnormalities * Cirrhosis or severe hepatic failure * Uncontrolled diabetes or requiring insulin * Consumption of alcohol and/or narcotics and/or other substances
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of randomized participants without virologic failure and with a viral load < 50 copies/mL at Week 52 | Week 52 |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants who complied with enfuvirtide and OB treatments as measured by pharmacokinetic score | Weeks 2, 4, 8, and 24 |
| Quality of life as assessed by medical outcomes study-HIV (MOS-HIV) questionnaire score | Day 0 (inclusion), Weeks 4, 12, 24, 28, 32, 44, and 52 or premature withdrawal |
| Change from baseline in viral load | Baseline up to Week 52 or premature withdrawal |
| Proviral deoxyribonucleic acid (DNA) level | Day 0 (inclusion), Weeks 28, and 52 or premature withdrawal |
| Time to reappearance of viral load above 50 copies/mL in randomized participants | 52 weeks |
| Changes from baseline in CD4 and CD8 cell counts | Day -35 (screening), Day 0 (inclusion), Weeks 4, 12, 24, 28, 36, 44, and 52 or premature withdrawal |
| Number of participants with virologic response (viral load < 50 copies/mL, 200 copies/mL, and 400 copies/mL) | Weeks 2, 4, 8, 12, 16, 24, 28, 32, 36, 44, and 52 |
| Number of participants with cause of virologic failure | Day 0 (inclusion), Weeks 2, 4, 8, 16, 28, 32, 36, 44, and 52 or premature withdrawal |
| Number of participants who complied with enfuvirtide treatment, as assessed by counting treatment units returned versus supplied | Weeks 4, 8, 12, 16, 24, 28, 32, 36, 44, and 52 |
| Number of participants with adverse events | Day 0 (inclusion), Weeks 2, 4, 8, 12, 16, 24, 28, 32, 36, 44, and 52 or premature withdrawal and follow-up (approximately up to 452 days) |
| Number of participants with missed treatment doses or injections as assessed by compliance questionnaire | Day 0 (inclusion), Weeks 4, 12, 24, 28, 32, 44, and 52 or premature withdrawal |
| Number of participants with injection site reaction | Day 0 (inclusion), Weeks 2, 4, 8, 12, 16, 24, 28, 32, 36, 44, and 52 or premature withdrawal and follow-up (approximately up to 452 days) |
| Number of virologic failure participants with reverse transcriptase, protease, and coating resistance mutations for plasma HIV-1 RNA and proviral DNA | Day 0 (inclusion) up to Week 52 |
Countries
France
Outcome results
None listed